Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Attention-Deficit/Hyperactivity Disorder01:30

Attention-Deficit/Hyperactivity Disorder

736
Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by persistent inattention, hyperactivity, and impulsivity. It affects approximately 5-8% of children globally, with around 60-70% of cases persisting into adulthood. ADHD has significant implications for educational attainment, social interactions, and occupational success.
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....
736
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

544
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
544
Drug Therapy01:28

Drug Therapy

239
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
239
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

806
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
806
Drugs Affecting Neurotransmitter Release or Uptake01:21

Drugs Affecting Neurotransmitter Release or Uptake

1.5K
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
1.5K
Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

2.1K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
2.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Towards the use of functional near-infrared spectroscopy as an assessment tool in disorders of consciousness.

Imaging neuroscience (Cambridge, Mass.)·2026
Same author

Detecting Awareness in the Intensive Care Unit Using Functional Near-Infrared Spectroscopy.

Annals of neurology·2025
Same author

Aortic Bioprosthetic Stenosis Leading to Heyde Syndrome.

JACC. Case reports·2025
Same author

Perspectives on Physical Activity and Learning from Children With and Without ADHD.

Sports (Basel, Switzerland)·2025
Same author

Publisher Correction: fNIRS reproducibility varies with data quality, analysis pipelines, and researcher experience.

Communications biology·2025
Same author

Assessing the consistency and sensitivity of the neural correlates of narrative stimuli using functional near-infrared spectroscopy.

Imaging neuroscience (Cambridge, Mass.)·2025

Related Experiment Video

Updated: Jan 13, 2026

Event Related Potentials ERPs and other EEG Based Methods for Extracting Biomarkers of Brain Dysfunction: Examples from Pediatric Attention Deficit/Hyperactivity Disorder ADHD
10:02

Event Related Potentials ERPs and other EEG Based Methods for Extracting Biomarkers of Brain Dysfunction: Examples from Pediatric Attention Deficit/Hyperactivity Disorder ADHD

Published on: March 12, 2020

16.6K

Medication vs. Movement in ADHD: Interaction Between Medication and Physical Activity on Neurocognitive Functioning.

Beverly-Ann Hoy1, Michelle Bi1, Matthew Lam1

  • 1Faculty of Education, Western University, London, ON N6G 1G7, Canada.

Brain Sciences
|October 29, 2025
PubMed
Summary
This summary is machine-generated.

Movement during executive functioning tasks boosts brain activity and performance in unmedicated children with ADHD, unlike their medicated peers. This suggests physical activity may aid attention in ADHD when medication is not an option.

Keywords:
ADHD medicationAttention-Deficit Hyperactivity Disorder (ADHD)children with ADHDcognitive and behavioural modulationcortical underarousal in ADHDfunctional near-infrared spectroscopymedication and physical activityphysical activity interventions

More Related Videos

Using Brain Activation nir-HEG/Q-EEG and Execution Measures CPTs in a ADHD Assessment Protocol
13:09

Using Brain Activation nir-HEG/Q-EEG and Execution Measures CPTs in a ADHD Assessment Protocol

Published on: April 1, 2018

10.9K
The Adventures of Fundi Intervention Based on the Cognitive and Emotional Processing in Attention Deficit Hyperactive Disorder Patients
05:48

The Adventures of Fundi Intervention Based on the Cognitive and Emotional Processing in Attention Deficit Hyperactive Disorder Patients

Published on: June 12, 2020

6.3K

Related Experiment Videos

Last Updated: Jan 13, 2026

Event Related Potentials ERPs and other EEG Based Methods for Extracting Biomarkers of Brain Dysfunction: Examples from Pediatric Attention Deficit/Hyperactivity Disorder ADHD
10:02

Event Related Potentials ERPs and other EEG Based Methods for Extracting Biomarkers of Brain Dysfunction: Examples from Pediatric Attention Deficit/Hyperactivity Disorder ADHD

Published on: March 12, 2020

16.6K
Using Brain Activation nir-HEG/Q-EEG and Execution Measures CPTs in a ADHD Assessment Protocol
13:09

Using Brain Activation nir-HEG/Q-EEG and Execution Measures CPTs in a ADHD Assessment Protocol

Published on: April 1, 2018

10.9K
The Adventures of Fundi Intervention Based on the Cognitive and Emotional Processing in Attention Deficit Hyperactive Disorder Patients
05:48

The Adventures of Fundi Intervention Based on the Cognitive and Emotional Processing in Attention Deficit Hyperactive Disorder Patients

Published on: June 12, 2020

6.3K

Area of Science:

  • Neuroscience
  • Developmental Psychology
  • Pediatrics

Background:

  • Pediatric Attention-Deficit/Hyperactivity Disorder (ADHD) is associated with cortical under-arousal.
  • Movement may compensate for under-arousal during attention-demanding tasks.
  • The effect of medication on movement's impact on ADHD is unclear.

Purpose of the Study:

  • To investigate how movement during executive functioning tasks affects dorsolateral prefrontal cortex (DLPFC) activation and inhibitory control in children with ADHD.
  • To examine the influence of medication status on these effects.

Main Methods:

  • Twenty-six children with ADHD (15 medicated, 11 unmedicated) and 24 controls performed a Stroop task.
  • Tasks were completed while seated (Stationary) and while pedaling a desk cycle (Movement).
  • Functional near-infrared spectroscopy (fNIRS) measured left DLPFC activation.

Main Results:

  • Unmedicated ADHD children showed increased left DLPFC activity and better Stroop task accuracy during movement.
  • Medicated ADHD children did not benefit from movement; some showed reduced DLPFC activation.
  • Controls exhibited increased DLPFC activation during movement, similar to unmedicated ADHD participants.

Conclusions:

  • Physical activity during executive tasks enhances DLPFC activation and inhibitory control in unmedicated ADHD children.
  • Medicated ADHD children did not show these benefits.
  • Movement may serve as a compensatory strategy for attention in ADHD when medication is not feasible or tolerated.